Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQLE | Q14534 | 7/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.74 |
| ▸ | ICMT | O60725 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | FNTA | P49354 | 1/20 | 0.53 |
| ▸ | FNTB | P49356 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595473 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL18037035 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL8512384 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL9738963 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL17312900 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL2636615 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL19228659 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL5595479 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL7299170 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL586128 | 1.00 | SQLE (0.78) | SQLEKMT2AMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724592-A2 | PREPARATION OF TERPENOID COMPOUNDS | Firmenich SA (CH) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724593-A2 | POLYPEPTIDES FOR PREPARING TERPENOID COMPOUNDS | Firmenich SA (CH) | 2026-04-15 | — | — | EP | disclosed |
| EP-4711360-A1 | PRODUCT | Givaudan SA (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062725-A1 | METHOD FOR PURIFYING (-)-AMBROX | GIVAUDAN SA (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20260043058-A1 | SHC ENZYMES AND ENZYME VARIANTS | GIVAUDAN SA (CH) | 2026-02-12 | — | — | US | disclosed |
| EP-3445755-B1 | A SOLID FORM OF (-)-AMBROX FORMED BY A BIOVERVERSION OF HOMOFARNESOL IN THE PRESENCE OF A BIOCATALYST | GIVAUDAN SA (CH) | 2026-01-07 | — | — | EP | disclosed |
| US-20250361536-A1 | SQUALENE HOPENE CYCLASE (SHC) VARIANTS | GIVAUDAN SA (CH) | 2025-11-27 | — | — | US | disclosed |
| US-12416027-B2 | Squalene hopene cyclase (SHC) variants | GIVAUDAN SA (CH) | 2025-09-16 | — | — | US | disclosed |
| US-12404531-B2 | Method for purifying (−)-Ambrox | GIVAUDAN SA (CH) | 2025-09-02 | — | — | US | disclosed |
| EP-4267547-B1 | PROCESS OF MAKING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-02-05 | — | — | EP | disclosed |
| US-5212164-A | Hypocholesterolemic and antiatherosclerotic agents | E. R. SQUIBB & SONS, INC. (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0534546-A1 | Farnesyl pyrophosphate analogs | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| US-5166386-A | Inhibit cholesterol biosynthesis | E. R. SQUIBB & SONS, INC. (US) | 1992-11-24 | — | — | US | disclosed |
| EP-0513761-A2 | Bisphosphonate squalene synthetase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| US-5157027-A | Anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5107011-A | Intermediates for anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1992-04-21 | — | — | US | disclosed |
| US-5025003-A | Anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0418814-A2 | Isoprenoid phosphinylformic acid squalene synthetase inhibitors and method for preparing the same | E.R. SQUIBB & SONS, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0409181-A2 | Phosphorus-containing squalene synthetase inhibitors and method for their preparation | E.R. SQUIBB & SONS, INC. (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0356866-A2 | Phosphorus-containing squalene synthetase inhibitors and method | E.R. SQUIBB & SONS, INC. (US) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260043058-A1 | SHC ENZYMES AND ENZYME VARIANTS | SQLE, DHCR7, CYP51A1 | SQLE 1/4885KMT2A 3526/4885MAPT 4866/4885 |
| US-20260062725-A1 | METHOD FOR PURIFYING (-)-AMBROX | TAS2R7, TAS2R3, TAS2R13 | SQLE 844/4885KMT2A 3026/4885MAPT 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.